We don't cater to customers in UAE, we only ship internationally.

Sipmax International

  • Enzamide 160 Tablets
  • Enzamide 160 Tablets

Enzamide 160 Tablets

Enzamide 160 Tablets Enzamide 160 Tablets contain enzalutamide, an oral anticancer medicine used for the treatment of advanced prostate cancer. It belongs to a group of medicines called androgen receptor inhibitors, which work by blocking the effects of male hormones that stimulate the growth of prostate cancer cells. By reducing the activity of these hormones, Enzamide helps slow disease progression and supports long-term management of prostate cancer.

Effects & Benefits Helps slow the growth and spread of prostate cancer cells. Blocks androgen receptor activity to reduce cancer progression. Used in metastatic and non-metastatic prostate cancer. Helps delay disease progression. May improve overall survival in eligible patients. Convenient once-daily oral treatment.

Read more
Brand Enzamide 160
Storage Temperature Store below 30°C in a cool and dry place. Protect from moisture and direct sunlight.
Dosage As directed by the treating physician.
Prescription Needed Yes
Composition Enzalutamide 160 mg
Strength 160 mg
Form Tablet
Pack Size 7 Tablets
Packaging 1 × 7 Tablets
Country of Origin Made In India
Manufacturer Intas Pharmaceuticals Ltd.

Enzamide 160 Tablets

Enzamide 160 Tablets Enzamide 160 Tablets contain enzalutamide, an oral anticancer medicine used for the treatment of advanced prostate cancer. It belongs to a group of medicines called androgen receptor inhibitors, which work by blocking the effects of male hormones that stimulate the growth of prostate cancer cells. By reducing the activity of these hormones, Enzamide helps slow disease progression and supports long-term management of prostate cancer.

Effects & Benefits Helps slow the growth and spread of prostate cancer cells. Blocks androgen receptor activity to reduce cancer progression. Used in metastatic and non-metastatic prostate cancer. Helps delay disease progression. May improve overall survival in eligible patients. Convenient once-daily oral treatment.

Related Products